For a better experience, Read this story in our App
-823.16
-253.20
-14.00
+ 1,626.00
+ 608.00
-823.16
-253.20
-253.20
-14.00
-14.00
+ 1,626.00
Join Sai Prabhakar, Principal research analyst at businessline, as he discusses Sun Pharma’s strategic acquisition of Checkpoint Therapeutics and its impact on the company’s growth. Learn about Sun Pharma’s shift towards specialty products, recent acquisitions, and future prospects in the pharmaceutical industry. Stay updated with market insights and investment recommendations.
--
Video host: Sai Prabhakar, Video Edit and Production: Renil S Varghese and Siddharth Mathew Cherian)
Published on March 14, 2025
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.